- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT04198766
Studie av INBRX-106 og INBRX-106 i kombinasjon med Pembrolizumab hos personer med lokalt avanserte eller metastatiske solide svulster (heksavalent OX40-agonist)
En åpen, multisenter, første-i-menneske, dose-eskalering, fase 1-studie av INBRX-106 og INBRX-106 i kombinasjon med Pembrolizumab hos personer med lokalt avanserte eller metastatiske solide svulster
This is a Phase 1/2, open-label, non-randomized, 4-part trial to determine the safety profile and identify the maximum tolerated dose (MTD) and/or recommended Phase 2 dose (RP2D) of INBRX 106 administered as a single agent or in combination with the anti-PD-1 checkpoint inhibitor (CPI) pembrolizumab (Keytruda®). KEYTRUDA is a registered trademark of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA.
Studieoversikt
Status
Forhold
Intervensjon / Behandling
- Legemiddel: INBRX-106 - Hexavalent OX40 agonist antibody
- Legemiddel: pembrolizumab 200 mg
- Legemiddel: pembrolizumab 400 mg
- Legemiddel: Carboplatin AUC-5
- Legemiddel: Pemetrexed 500 mg/m2
- Legemiddel: Cisplatin 75mg/m2
- Legemiddel: Carboplatin AUC-6
- Legemiddel: Paclitaxel 200mg/m2
- Legemiddel: Nab paclitaxel 100mg/m2
- Legemiddel: Gemcitabine (1000 mg/m2)
Studietype
Registrering (Antatt)
Fase
- Fase 2
- Fase 1
Kontakter og plasseringer
Studiekontakt
- Navn: Study Director - Inhibrx Biosciences, Inc
- Telefonnummer: 858-500-7833
- E-post: clinicaltrials@inhibrx.com
Studiesteder
-
-
California
-
Duarte, California, Forente stater, 91010
- Aktiv, ikke rekrutterende
- City of Hope
-
Glendale, California, Forente stater, 91204
- Rekruttering
- Oncura Health
-
Ta kontakt med:
- Elizabeth Brown
- E-post: Elizabeth.Brown@lahomg.com
-
Hovedetterforsker:
- Sungwon Kyung, MD
-
La Jolla, California, Forente stater, 92037
- Har ikke rekruttert ennå
- UC San Diego Health - Moores Cancer Center
-
Hovedetterforsker:
- Lyudmila Bazhenova, MD
-
Los Angeles, California, Forente stater, 90027
- Rekruttering
- California Research Institute
-
Hovedetterforsker:
- Ghassan Al-Jazayrly, MD
-
Ta kontakt med:
- Swati Shrestha
- E-post: sw@caresinst.com
-
Los Angeles, California, Forente stater, 90069
- Rekruttering
- Valkyrie Clinical Trials
-
Hovedetterforsker:
- David Berz, MD
-
Ta kontakt med:
- Myo Zaw
- E-post: myo.zaw@valkyrieclinicaltrials.com
-
Los Angeles, California, Forente stater, 90033
- Har ikke rekruttert ennå
- University of Southern California Norris Comprehensive Cancer Center
-
Hovedetterforsker:
- Jorge Nieva, MD
-
Murrieta, California, Forente stater, 92562
- Rekruttering
- Valkyrie Clinical Trials
-
Hovedetterforsker:
- David Berz, MD
-
Ta kontakt med:
- Isabella Gudino
- E-post: Isabella.gudino@vctcare.com
-
Santa Rosa, California, Forente stater, 95403
- Rekruttering
- Providence Medical Foundation
-
Hovedetterforsker:
- Ian Anderson, MD
-
Ta kontakt med:
- Clinical Research Coordinator
- Telefonnummer: 1181 707-521-3810
- E-post: jackson.barnard@providence.org
-
-
Colorado
-
Lakewood, Colorado, Forente stater, 80228
- Har ikke rekruttert ennå
- Valkyrie Clinical Trials - Colorado
-
Hovedetterforsker:
- Jason Henry, MD
-
-
Florida
-
Clermont, Florida, Forente stater, 34711
- Rekruttering
- Clermont Oncology Center
-
Hovedetterforsker:
- Gopal Kunta, MD
-
Ta kontakt med:
- Kiran Penta
- E-post: kiran@aorcorp.com
-
Orange City, Florida, Forente stater, 32763
- Rekruttering
- Mid Florida Hematology and Oncology Center
-
Hovedetterforsker:
- Santosh Nair, MD
-
Ta kontakt med:
- Kiran Penta
- E-post: kiran@aorcorp.com
-
-
Georgia
-
Atlanta, Georgia, Forente stater, 30322
- Aktiv, ikke rekrutterende
- Winship Cancer Institute - Emory University
-
-
Illinois
-
Chicago, Illinois, Forente stater, 60612
- Har ikke rekruttert ennå
- University of Illinois Cancer Center
-
Hovedetterforsker:
- Frank Weinberg, MD, PhD
-
Chicago, Illinois, Forente stater, 60637
- Aktiv, ikke rekrutterende
- The University of Chicago Medical Center
-
-
Iowa
-
Iowa City, Iowa, Forente stater, 52242
- Rekruttering
- University of Iowa
-
Hovedetterforsker:
- Douglas Laux, MD
-
Ta kontakt med:
- Jordan Harrelson
- Telefonnummer: 319-467-5831
- E-post: Jordan-harrelson@uiowa.edu
-
-
Kentucky
-
Louisville, Kentucky, Forente stater, 40202
- Rekruttering
- Norton Cancer Institute
-
Hovedetterforsker:
- John Hamm, MD
-
Ta kontakt med:
- Jenn Broadway, RN
- Telefonnummer: 19535 502-629-2500
- E-post: Jennifer.Broadway@nortonhealthcare.org
-
-
Michigan
-
Detroit, Michigan, Forente stater, 48202
- Rekruttering
- Henry Ford Cancer Institute
-
Hovedetterforsker:
- Amy Weise, MD
-
Ta kontakt med:
- Mahmoud Hossami
- Telefonnummer: 313-725-7842
- E-post: mhossam1@hfhs.org
-
Detroit, Michigan, Forente stater, 48201
- Fullført
- Barbara Ann Karmanos Cancer Institute
-
Grand Rapids, Michigan, Forente stater, 49546
- Aktiv, ikke rekrutterende
- START Midwest
-
-
Minnesota
-
Saint Louis Park, Minnesota, Forente stater, 55426
- Aktiv, ikke rekrutterende
- HealthPartners Cancer Research Center
-
Saint Paul, Minnesota, Forente stater, 55101
- Fullført
- HealthPartners Cancer Research Center (Regions Hospital)
-
-
Missouri
-
St Louis, Missouri, Forente stater, 63110
- Har ikke rekruttert ennå
- Washington University in St. Louis School of Medicine
-
Hovedetterforsker:
- Brett Herzog, MD, PhD
-
-
Montana
-
Billings, Montana, Forente stater, 59102
- Fullført
- Intermountain Health Cancer Centers of Montana
-
-
Nebraska
-
Grand Island, Nebraska, Forente stater, 68803
- Har ikke rekruttert ennå
- Nebraska Cancer Specialists - Grand Island
-
Hovedetterforsker:
- Ralph Hauke, MD
-
Omaha, Nebraska, Forente stater, 68130
- Rekruttering
- Nebraska Cancer Specialists
-
Hovedetterforsker:
- Ralph Hauke, MD
-
Ta kontakt med:
- Lindsey Becker
- Telefonnummer: 402-691-5255
- E-post: lbecker@nebraskacancer.com
-
-
New Jersey
-
Camden, New Jersey, Forente stater, 08103
- Har ikke rekruttert ennå
- MD Anderson Cancer Center at Cooper
-
Hovedetterforsker:
- Polina Khrizman, MD
-
-
New York
-
The Bronx, New York, Forente stater, 10467
- Aktiv, ikke rekrutterende
- Montefiore Medical Center
-
-
Ohio
-
Cleveland, Ohio, Forente stater, 44195
- Aktiv, ikke rekrutterende
- Cleveland Clinic
-
-
Oregon
-
Portland, Oregon, Forente stater, 97213
- Aktiv, ikke rekrutterende
- Providence Portland Medical Center
-
-
Pennsylvania
-
Allentown, Pennsylvania, Forente stater, 18103
- Har ikke rekruttert ennå
- Lehigh Valley Health Network
-
Hovedetterforsker:
- Muhammad Rizvi, MD
-
-
Tennessee
-
Knoxville, Tennessee, Forente stater, 37923
- Har ikke rekruttert ennå
- University of Tennessee Health Science Center
-
Hovedetterforsker:
- Sean Jordan, MD
-
Nashville, Tennessee, Forente stater, 37204
- Aktiv, ikke rekrutterende
- Vanderbilt University School of Medicine
-
-
Texas
-
Dallas, Texas, Forente stater, 75230
- Fullført
- Sarah Cannon Research Institute at Mary Crowley
-
El Paso, Texas, Forente stater, 79915
- Fullført
- Renovatio Clinical - El Paso
-
San Antonio, Texas, Forente stater, 78229
- Fullført
- NEXT Oncology
-
The Woodlands, Texas, Forente stater, 77380
- Fullført
- Renovatio Clinical
-
Tyler, Texas, Forente stater, 75701
- Rekruttering
- The University of Texas Health Science Center at Tyler
-
Ta kontakt med:
- Chaney Story
- E-post: Chaney.Story@uttyler.edu
-
Hovedetterforsker:
- Erminia Massarelli, MD, PhD, MS
-
-
Virginia
-
Fairfax, Virginia, Forente stater, 22031
- Fullført
- Virginia Cancer Specialists
-
-
Wisconsin
-
Milwaukee, Wisconsin, Forente stater, 53226
- Rekruttering
- Froedtert Hospital and the Medical College of Wisconsin
-
Hovedetterforsker:
- Jonathan Thompson, MD
-
Ta kontakt med:
- Ellen Smith
- E-post: eksmith@mcw.edu
-
-
-
-
-
Singapore, Singapore
- Fullført
- Curie Oncology
-
Singapore, Singapore
- Fullført
- Icon Cancer Centre Farrer Park
-
Singapore, Singapore
- Fullført
- Icon Cancer Centre Mount Alvernia
-
-
-
-
-
Busan, Sør -Korea
- Har ikke rekruttert ennå
- Inje University College of Medicine
-
Hovedetterforsker:
- IL-Hwan Kim, MD, PhD
-
Cheongju-si, Sør -Korea
- Har ikke rekruttert ennå
- Chungbuk National University Hospital
-
Hovedetterforsker:
- Ki-Hyeong Lee, MD
-
Gyeonggi-do, Sør -Korea
- Rekruttering
- The Catholic University of Korea, St. Vincent's Hospital
-
Hovedetterforsker:
- Byoung Yong Shim
-
Hwasun, Sør -Korea
- Har ikke rekruttert ennå
- Chonnam National University Hwasun Hospital
-
Hovedetterforsker:
- In-Jae Oh, MD, MS, PhD
-
Incheon, Sør -Korea
- Har ikke rekruttert ennå
- Gachon University Gil Medical Center
-
Hovedetterforsker:
- Eun Kyung Cho, PhD, M.S
-
Seongnam-si, Sør -Korea
- Har ikke rekruttert ennå
- CHA Bundang Medical Center
-
Hovedetterforsker:
- Yoon Beom Sang
-
Seoul, Sør -Korea
- Rekruttering
- Asan Medical Center
-
Ta kontakt med:
- Bokyeong Jung, RN
- E-post: bokyeong_jung@amc.seoul.kr
-
Hovedetterforsker:
- Dae Ho Lee, MD
-
Seoul, Sør -Korea
- Rekruttering
- Severance Hospital, Yonsei University Health System
-
Ta kontakt med:
- Miyeon Lee
- E-post: lee_my@yuhs.ac
-
Hovedetterforsker:
- Sun Mun Lim
-
Seoul, Sør -Korea
- Rekruttering
- The Catholic University of Korea Seoul St. Mary's Hospital,
-
Hovedetterforsker:
- SookHee Hong
-
Ta kontakt med:
- Na Ayn
- E-post: Ahnna331@gmail.com
-
Seoul, Sør -Korea
- Har ikke rekruttert ennå
- Korea University Anam Hospital
-
Hovedetterforsker:
- Yoon Ji Choi, MD, MS, PhD
-
Seoul, Sør -Korea
- Har ikke rekruttert ennå
- Hanyang University Seoul Hospital
-
Hovedetterforsker:
- Myung- Ju Ahn, MD, PhD, MS
-
Seoul, Sør -Korea
- Har ikke rekruttert ennå
- Korea University Guro Hospital
-
Hovedetterforsker:
- Sung Yong Lee
-
Hovedetterforsker:
- Sung Yong Lee, MD, MS, PhD
-
Suwon, Sør -Korea
- Har ikke rekruttert ennå
- Ajou University Hospital
-
Hovedetterforsker:
- Yong-Won Choi, MD
-
-
-
-
-
Changhua, Taiwan
- Aktiv, ikke rekrutterende
- Changhua Christian Hospital (CCH)
-
Kaohsiung City, Taiwan
- Aktiv, ikke rekrutterende
- E-Da Cancer Hospital
-
Kaohsiung City, Taiwan
- Aktiv, ikke rekrutterende
- Kaohsiung Medical University Chung-Ho Memorial Hospital (KMUH)
-
Tainan, Taiwan
- Aktiv, ikke rekrutterende
- National Cheng Kung University Hospital
-
Taipei, Taiwan
- Fullført
- Taipei Veterans General Hospital
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Beskrivelse
Select Inclusion Criteria:
- Males or females aged ≥18 years.
- Parts 1 and 3 (escalation cohorts): Subjects with locally advanced or metastatic non resectable solid tumors, whose disease has progressed despite all standard therapies or for whom no further standard or clinically acceptable therapy exists.
- Part 2 (single-agent expansion cohort): Subjects with NSCLC, melanoma, HNSCC, G/GEA, RCC, or TCC, with histologically confirmed, locally advanced or metastatic, non-resectable disease, which has progressed despite all standard therapies including CPI or for whom no standard or clinically acceptable therapy exists.
- Part 4 (expansion cohorts in combination with pembrolizumab, with or without chemotherapy): Subjects with melanoma (all types), HNSCC, G/GEA, RCC, TCC, NSCLC, or MSI-high, TMB-high, MMR-deficient tumors, with histologically confirmed, locally advanced or metastatic, non resectable disease, which is either CPI-naive (melanoma, HNSCC, NPC) or progressed despite all standard therapies including CPI (NSCLC, RCC, TCC, uveal melanoma, MSI-high, TMB-high, or MMR-deficient solid tumors) or for whom no standard or clinically acceptable therapy exists.
- For Cohort F3 (NSCLC), subjects may have progressed on no more than 2 lines of standard therapy that must include at least one PD-1/L1 regimen.
- For Cohort F4 (HNSCC and NPC), subjects may be previously treated with no more than 1 prior chemotherapy regimen in metastatic setting. Prior PD-1/L1 in curative (neo-adjuvant/adjuvant) setting is allowed only if completed >/= 6 months prior to progression to local recurrence or metastatic disease.
- For Cohort F8, subjects must have previously untreated, histologically confirmed Stage II, IIIA or IIIB (T3-4N2) NSCLC. Lymph node disease requires histologic confirmation, while T3 disease requires only radiographic documentation. Subjects need to be able to undergo planned surgery.
- All subjects with non-squamous NSCLC must have documentation of absence of tumor activating EGFR mutations and absence of ALK gene rearrangements.
- PD-L1 by IHC (22C3): Parts 1 and 3: IHC optional. Part 2: IHC result mandatory but any score allowed. Combined Positive Score (CPS) ≥ 1% (or Tumor Proportion Score ≥50% for NSCLC; for TMB-high tumors, any TPS% is allowed). Part 4: Combined Positive Score (CPS) ≥ 1% (or Tumor Proportion Score ≥50% for NSCLC; for TMB-high tumors, any TPS% is allowed). For Cohort F8, any TPS (including 0%) is acceptable.
- Adequate hematologic, coagulation, hepatic and renal function and ECOG score as defined per protocol.
Select Exclusion Criteria:
- Prior exposure to OX40 agonists. Exposure to anti-PD-1 and/or anti PD-L2 CPIs or an agent targeting other co-stimulatory T-cell receptor pathways.
- Receipt of any investigational product or any approved anticancer drug(s) or biological product(s) within 4 weeks prior to the first dose of study drug with certain exceptions.
- Hematologic malignancies (e.g., ALL, AML, MDS, CLL, CML, NHL, Hodgkin's lymphoma and multiple myeloma)
- Prior or concurrent malignancies. Exception: Subjects with a prior or concurrent malignancy whose natural history or treatment does not have the potential to interfere with the safety or efficacy assessments of INBRX-106.
- Grade ≥ 3 immune-related adverse events (irAEs) or irAE that lead to discontinuation of prior immunotherapy. Some exceptions as defined per protocol apply.
- Active autoimmune disease or documented history of autoimmune disease that required systemic steroids or other immunosuppressive medications. Certain exceptions as defined in protocol apply.
- Diagnosis of immunodeficiency or treatment with systemic immunosuppressive medications within 7 days prior to the first dose of study drug. Certain exceptions as defined in protocol apply.
- History of hepatitis B, hepatitis C, or human immunodeficiency virus (HIV) infection. Exceptions as defined in protocol apply.
- Active interstitial lung disease (ILD) or pneumonitis or a history of ILD or pneumonitis requiring treatment with steroids or other immunosuppressive medications.
- Clinically significant cardiac condition, including myocardial infarction, uncontrolled angina, viral myocarditis, cerebrovascular accident, or other acute uncontrolled heart disease < 3 months prior to enrollment on this trial; left ventricular ejection fraction (LVEF) < 50%; New York Heart Association (NYHA) Class III or IV congestive heart failure; or uncontrolled hypertension; or oxygen saturation <92% on room air.
- Active, hemodynamically significant pulmonary embolism within 12 weeks prior to enrollment on this trial.
- Major surgery within 4 weeks prior to enrollment on this trial.
- Anti-infectious drug treatments (i.e., antibiotics) within 4 weeks prior to the first dose of study drug.
- Prior organ allograft transplantations or allogeneic peripheral blood stem cell (PBSC) or bone marrow (BM) transplantation.
- Additional in- and exclusion criteria per protocol.
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Behandling
- Tildeling: Randomisert
- Intervensjonsmodell: Sekvensiell tildeling
- Masking: Enkelt
Våpen og intervensjoner
Deltakergruppe / Arm |
Intervensjon / Behandling |
|---|---|
|
Eksperimentell: Part 1 INBRX-106 Escalation (Not Recruiting)
INBRX-106 will be escalated in subjects with locally advanced or metastatic solid tumors. |
The active ingredient of INBRX-106 is a recombinant, humanized, hexavalent IgG antibody that targets the human OX40 receptor (TNFRSF4). |
|
Eksperimentell: Part 3 INBRX-106 Escalation in Combination with pembrolizumab (Not Recruiting)
INBRX-106 will be escalated, in combination with pembrolizumab, in subjects with locally advanced or metastatic solid tumors. |
The active ingredient of INBRX-106 is a recombinant, humanized, hexavalent IgG antibody that targets the human OX40 receptor (TNFRSF4). pembrolizumab 200 mg by intravenous (IV) infusion, given on Day 1 of each 21-day cycle.
Andre navn:
|
|
Eksperimentell: Part 2 (Cohorts C1/C2) INBRX-106 Escalation in Various Solid Tumor Types (Not Recruiting)
Subjects with melanoma (any type), head and neck squamous cell carcinoma, renal cell carcinoma, urothelial carcinoma or MSI/TMB-high tumors that are relapsed or refractory to prior checkpoint inhibitor (CPI) therapy will be treated with INBRX-106 |
The active ingredient of INBRX-106 is a recombinant, humanized, hexavalent IgG antibody that targets the human OX40 receptor (TNFRSF4). pembrolizumab 200 mg by intravenous (IV) infusion, given on Day 1 of each 21-day cycle.
Andre navn:
|
|
Eksperimentell: Part 2 (Cohort C3) INBRX-106 Escalation in NSCLC (Not Recruiting)
Subjects with non-small cell carcinoma relapsed or refractory to prior checkpoint inhibitor (CPI) therapy will be treated with INBRX-106 |
pembrolizumab 200 mg by intravenous (IV) infusion, given on Day 1 of each 21-day cycle.
Andre navn:
|
|
Eksperimentell: Part 4 (Cohort F3a) INBRX-106 Expansion in Combination with pembrolizumab in NSCLC (Not Recruiting)
Subjects with non-small cell lung cancer will be treated with alternating dosing of INBRX-106 0.3 mg/kg Q6W and 400 mg pembrolizumab IV Q6W. This is one of the randomized cohorts. |
The active ingredient of INBRX-106 is a recombinant, humanized, hexavalent IgG antibody that targets the human OX40 receptor (TNFRSF4). pembrolizumab 400 mg by IV infusion given on Day 1 of alternating 21-day cycles (every 6 weeks)
Andre navn:
|
|
Eksperimentell: Part 4 (Cohort F3b) INBRX-106 Expansion in Combination with pembrolizumab in NSCLC (Not Recruiting)
Subjects with non-small cell lung cancer will be given a 0.3 mg/kg priming dose of INBRX-106 in cycle 1, followed by 0.1 mg/kg INBRX-106 and 200 mg pembrolizumab IV every 3 weeks in subsequent cycles. This is one of the randomized cohorts. |
The active ingredient of INBRX-106 is a recombinant, humanized, hexavalent IgG antibody that targets the human OX40 receptor (TNFRSF4). pembrolizumab 200 mg by intravenous (IV) infusion, given on Day 1 of each 21-day cycle.
Andre navn:
pembrolizumab 400 mg by IV infusion given on Day 1 of alternating 21-day cycles (every 6 weeks)
Andre navn:
|
|
Aktiv komparator: Part 4 (Cohort F3c) Pembrolizumab Expansion Arm (Not Recruiting)
Subjects with non-small cell lung cancer will be treated with 200 mg pembrolizumab IV every 3 weeks. This is one of the randomized cohorts. |
The active ingredient of INBRX-106 is a recombinant, humanized, hexavalent IgG antibody that targets the human OX40 receptor (TNFRSF4). |
|
Eksperimentell: Part 4 (Cohort F3d) INBRX-106 Expansion in Combination with pembrolizumab in NSCLC (Not-Recruiting)
Subjects with non-small cell lung cancer will be treated concurrently every 6 weeks with INBRX-106 0.1 mg/kg and 200 mg pembrolizumab IV every 3 weeks. This is one of the randomized cohorts. |
The active ingredient of INBRX-106 is a recombinant, humanized, hexavalent IgG antibody that targets the human OX40 receptor (TNFRSF4). |
|
Eksperimentell: Part 4 (Cohort F4) INBRX-106 Expansion in Combination with pembrolizumab (Not Recruiting)
Subjects with melanoma (any type), head and neck squamous cell carcinoma (non-nasopharyngeal) OR nasopharyngeal carcinoma, MSI-high, TMB-high or MMR-deficient tumors, will be treated with INBRX-106 in combination with 200mg pembrolizumab IV every 3 weeks. |
The active ingredient of INBRX-106 is a recombinant, humanized, hexavalent IgG antibody that targets the human OX40 receptor (TNFRSF4). pembrolizumab 200 mg by intravenous (IV) infusion, given on Day 1 of each 21-day cycle.
Andre navn:
|
|
Eksperimentell: Part 4 (Cohort F5)INBRX-106 Expansion with pembrolizumab in MSI/TMB-high/MMRd tumors Not Recuriting
Subjects with solid tumors that have confirmed MSI-high, TMB-high or MMR-deficient states who are relapsed or refractory to checkpoint inhibitor (CPI) therapy will be treated with INBRX-106 and 200 mg pembrolizumab IV every 3 weeks |
The active ingredient of INBRX-106 is a recombinant, humanized, hexavalent IgG antibody that targets the human OX40 receptor (TNFRSF4). pembrolizumab 200 mg by intravenous (IV) infusion, given on Day 1 of each 21-day cycle.
Andre navn:
|
|
Eksperimentell: Part 4 (Cohort F6) INBRX-106 Expansion with pembrolizumab in Uveal Melanoma (Not Recruiting)
Subjects with ocular (uveal) melanoma who are relapsed or refractory to checkpoint inhibitor (CPI) therapy will be treated with INBRX-106 and 200 mg pembrolizumab IV every 3 weeks |
The active ingredient of INBRX-106 is a recombinant, humanized, hexavalent IgG antibody that targets the human OX40 receptor (TNFRSF4). pembrolizumab 200 mg by intravenous (IV) infusion, given on Day 1 of each 21-day cycle.
Andre navn:
carboplatin AUC-5 by intravenous (IV) infusion, given on Day 1 of each 21-day cycle of cycles 1-4. Cohort F8, carboplatin AUC-5 by intravenous (IV) infusion, given on Day 1 of each 21-day cycle of cycle 2-4. pemetrexed 500 mg/m2 by IV infusion given on Day 1 of each 21-Day cycle for up to 35 cycles. In Cohort F8, pemetrexed 500 mg/m2 by IV infusion given on Day 1 of each 21-Day cycle of cycles 1-4.
Andre navn:
|
|
Eksperimentell: Part 4 (Cohort F7a) INBRX-106 Expansion with pembrolizumab, pemetrexed and carboplatin in NSCLC
This Arm is no longer recruiting. Subjects with advanced/metastatic NSCLC, any PD-L1 TPS will be treated with INBRX-106 0.1mg/kg, 200mg pembrolizumab, 500mg/m2 pemetrexed and carboplatin AUC-5 IV every 3 weeks |
The active ingredient of INBRX-106 is a recombinant, humanized, hexavalent IgG antibody that targets the human OX40 receptor (TNFRSF4). pembrolizumab 200 mg by intravenous (IV) infusion, given on Day 1 of each 21-day cycle.
Andre navn:
pemetrexed 500 mg/m2 by IV infusion given on Day 1 of each 21-Day cycle for up to 35 cycles. In Cohort F8, pemetrexed 500 mg/m2 by IV infusion given on Day 1 of each 21-Day cycle of cycles 1-4.
Andre navn:
cisplatin 75mg/m2 by intravenous (IV) infusion, given on Day 1 of each 21-day cycle of cycles 1-4 |
|
Eksperimentell: Part 4 (Cohort F7b) INBRX-106 Expansion with pembrolizumab, pemetrexed and cisplatin in NSCLC
This Arm is no longer recruiting. Subjects with advanced/metastatic NSCLC, any PD-L1 TPS will be treated with INBRX-106 0.1mg/kg, 200mg pembrolizumab, 500mg/m2 pemetrexed and 75mg/m2 cisplatin IV every 3 weeks |
The active ingredient of INBRX-106 is a recombinant, humanized, hexavalent IgG antibody that targets the human OX40 receptor (TNFRSF4). pembrolizumab 200 mg by intravenous (IV) infusion, given on Day 1 of each 21-day cycle.
Andre navn:
carboplatin AUC-6 by intravenous (IV) infusion, given on Day 1 of each 21-day cycle of cycles 1-4 paclitaxel 200mg/m2 by intravenous (IV) infusion, given on Day 1 of each 21-day cycle of cycles 1-4 Nab paclitaxel 100mg/m2 by intravenous (IV) infusion, given on Days 1, 8 and 15 of each 21-day cycle of cycles 1-4 |
|
Eksperimentell: Part 4(Cohort F7c)INBRX-106 Expansion with pembrolizumab, (Nab)-paclitaxel and carboplatin in NSCLC
This Arm is no longer recruiting. Subjects with advanced/metastatic NSCLC, any PD-L1 TPS will be treated with INBRX-106 0.1mg/kg, 200mg pembrolizumab, 200mg/m2 paclitaxel and carboplatin AUC-6 IV every 3 weeks OR INBRX-106, 200mg pembrolizumab, 100mg/m2 nab-paclitaxel (dosed Days 1,8 and 15 every cycle) and carboplatin AUC-6 IV every 3 weeks. Treating physician to determine if paclitaxel or nab-paclitaxel will be given |
The active ingredient of INBRX-106 is a recombinant, humanized, hexavalent IgG antibody that targets the human OX40 receptor (TNFRSF4). pembrolizumab 200 mg by intravenous (IV) infusion, given on Day 1 of each 21-day cycle.
Andre navn:
|
|
Eksperimentell: Part 4(Cohort F8)INBRX-106 with pembrolizumab, cisplatin and gemcitabine or pemetrexed in NSCLC
Subjects with resectable Stage II, IIIA or IIIB (T3-4N2) NSCLC , any PD-L1 TPS will receive neoadjuvant treatment with INBRX-106 0.1 mg/kg, 200 mg pembrolizumab, cisplatin 75 mg/m2 (dosed Day 1 only) with gemcitabine 1000 mg/m2 (dosed on Days 1 and 8) for patients with squamous cell NSCLC given every 3 weeks OR neoadjuvant treatment with INBRX-106 0.1 mg/kg, 200 mg pembrolizumab, cisplatin 75 mg/m2 with pemetrexed 500 mg/m2 for patients with non-squamous cell NSCLC given every 3 weeks. Carboplatin AUC5 (dosed on Day 1 only) can be substituted for Cisplatin for subjects who are clinically considered ineligible or unsuitable for cisplatin per the Investigator's discretion or institution SOPs. Neoadjuvant treatment will be given for up to 4 cycles followed by surgery (lobectomy, bilobectomy or pneumonectomy). After surgery, all patients will receive adjuvant treatment consisting of INBRX-106 0.1 mg/kg, 200 mg pembrolizumab given every 3 weeks for up to 13 cycles. |
The active ingredient of INBRX-106 is a recombinant, humanized, hexavalent IgG antibody that targets the human OX40 receptor (TNFRSF4). pembrolizumab 200 mg by intravenous (IV) infusion, given on Day 1 of each 21-day cycle.
Andre navn:
carboplatin AUC-5 by intravenous (IV) infusion, given on Day 1 of each 21-day cycle of cycles 1-4. Cohort F8, carboplatin AUC-5 by intravenous (IV) infusion, given on Day 1 of each 21-day cycle of cycle 2-4. pemetrexed 500 mg/m2 by IV infusion given on Day 1 of each 21-Day cycle for up to 35 cycles. In Cohort F8, pemetrexed 500 mg/m2 by IV infusion given on Day 1 of each 21-Day cycle of cycles 1-4.
Andre navn:
cisplatin 75mg/m2 by intravenous (IV) infusion, given on Day 1 of each 21-day cycle of cycles 1-4 Gemcitabine 1000 mg/m2 given by intravenous (IV) infusion on Days 1 and 8 of each 21-day cycle of cycles 1-4 |
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Frequency of adverse events of INBRX-106 as single agent and in combination with pembrolizumab
Tidsramme: ~2 years
|
Adverse events will be assessed by the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE), version 5.0 |
~2 years
|
|
Severity of adverse events of INBRX-106 as single agent and in combination with pembrolizumab
Tidsramme: ~2 years
|
Adverse events will be assessed by the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE), version 5.0 |
~2 years
|
|
MTD and/or RP2D of INBRX-106 as single agent and in combination with pembrolizumab
Tidsramme: ~2 years
|
Maximum Tolerated Dose (MTD) and/or Recommended Phase 2 Dose (RP2D) of INBRX-106 and INBRX-106 in combination with pembrolizumab |
~2 years
|
|
Antitumor activity of INBRX-106 in combination with pembrolizumab in expansion cohorts
Tidsramme: ~2 years
|
The evaluation of efficacy will be based on the subject's measurable disease using RECIST v1.1 |
~2 years
|
|
Frequency and severity of adverse events of INBRX-106 in combination with pembrolizumab and chemotherapy in adults with locally advanced or metastatic NSCLC or resectable Stage II, IIIA or IIIB (T3-4N2) NSCLC
Tidsramme: ~2 years
|
Adverse events will be assessed by the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE), version 5.0 |
~2 years
|
|
To assess the antitumor activity of INBRX-106 in combination with pembrolizumab and platinum doublet chemotherapy as neoadjuvant/adjuvant therapy in adult subjects with NSCLC. (Cohort F8)
Tidsramme: ~2 years
|
Major pathological response (mPR) and pathological complete response (cPR) criteria. |
~2 years
|
Sekundære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Area under the serum concentration time curve (AUC) of INBRX-106
Tidsramme: ~2 years
|
Area under the serum concentration time curve (AUC) of INBRX-106 as a single agent and in combination with pembrolizumab with or without chemotherapy will be determined. |
~2 years
|
|
Maximum observed serum concentration (Cmax) of INBRX-106
Tidsramme: ~2 years
|
Maximum observed serum concentration (Cmax) of INBRX-106 as a single agent and in combination with pembrolizumab with or without chemotherapy will be determined. |
~2 years
|
|
Trough observed serum concentration (Ctrough) of INBRX-106
Tidsramme: ~2 years
|
Trough observed serum concentration (Ctrough) of INBRX-106 as a single agent and in combination with pembrolizumab with or without chemotherapy will be determined. |
~2 years
|
|
Time to Cmax (Tmax) of INBRX-106
Tidsramme: ~2 years
|
Time to Cmax (Tmax) of INBRX-106 as a single agent and in combination with pembrolizumab with or without chemotherapy will be determined. |
~2 years
|
|
Immunogenicity of INBRX-106
Tidsramme: ~2 years
|
Frequency of anti-drug antibodies (ADA) against INBRX-106 as a single agent and in combination with pembrolizumab with or without chemotherapy will be determined. |
~2 years
|
Andre resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Anti-tumor activity of INBRX-106 as single agent and in combination with pembrolizumab with or without chemotherapy
Tidsramme: ~2 years
|
Tumor response will be determined by the revised Response Evaluation Criteria in Solid Tumors version 1.1 (RECISTv1.1). |
~2 years
|
|
Anti-tumor activity of INBRX-106 as single agent and in combination with pembrolizumab with or without chemotherapy
Tidsramme: ~2 years
|
Tumor response will be determined by Response Evaluation Criteria in Solid Tumors (RECIST v1.1). |
~2 years
|
Samarbeidspartnere og etterforskere
Sponsor
Samarbeidspartnere
Etterforskere
- Studieleder: Clinical Lead, Inhibrx Biosciences, Inc
Publikasjoner og nyttige lenker
Studierekorddatoer
Studer hoveddatoer
Studiestart (Faktiske)
Primær fullføring (Antatt)
Studiet fullført (Antatt)
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Faktiske)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Nøkkelord
- Hode- og nakkekreft
- Lungekreft
- NSCLC
- Ikke-småcellet lungekreft
- Karsinom
- Neoplasmer
- Immunterapi
- Pembrolizumab
- Kjemoterapi
- Keytruda
- HNSCC
- Neoadjuvans
- Antineoplastiske midler
- Adjuvans
- Solide svulster
- Munnkreft
- Orofaryngeal kreft
- INBRX-106
- Antineoplastiske midler, immunologiske
- Neoplasmer i hode og nakke
- Neoplasmer, kjertel og epitel
- Neoplasmer etter histologisk type
- Neoplasmer etter nettsted
- Plateepitelkarsinom i hode og nakke
- Molekylære mekanismer for farmakologisk virkning
- PD-L1 positiv
- Neoplasmer, plateepitel
- Karsinom, plateepitel
- Hypopharyngeal kreft
- Fase 1 og Fase 2
- Fase 1 og fase 2 kliniske forsøk
- OX40 reseptoragonist
Ytterligere relevante MeSH-vilkår
- Urogenitale sykdommer
- Munnsykdommer
- Stomatognatiske sykdommer
- Urogenitale neoplasmer
- Mannlige urogenitale sykdommer
- Nyresykdommer
- Urologiske sykdommer
- Kvinnelige urogenitale sykdommer
- Kvinnelige urogenitale sykdommer og graviditetskomplikasjoner
- Sykdommer i luftveiene
- Gastrointestinale neoplasmer
- Neoplasmer i fordøyelsessystemet
- Sykdommer i fordøyelsessystemet
- Gastrointestinale sykdommer
- Magesykdommer
- Lungesykdommer
- Adenokarsinom
- Neoplasmer i luftveiene
- Thoracale neoplasmer
- Hudsykdommer
- Urologiske neoplasmer
- Otorhinolaryngologiske sykdommer
- Nevroektodermale svulster
- Neoplasmer, kjønnsceller og embryonale
- Neoplasmer, nervevev
- Nyre-neoplasmer
- Karsinom, bronkogent
- Bronkiale neoplasmer
- Nevroendokrine svulster
- Faryngeale neoplasmer
- Otorhinolaryngologiske neoplasmer
- Faryngeale sykdommer
- Nevi og melanomer
- Neoplasmer i huden
- Hud- og bindevevssykdommer
- Plateepitelkarsinom i hode og nakke
- Neoplasmer
- Neoplasmer i magen
- Karsinom
- Lungeneoplasmer
- Karsinom, plateepitel
- Karsinom, nyrecelle
- Karsinom, ikke-småcellet lunge
- Neoplasmer i hode og nakke
- Melanom
- Neoplasmer etter histologisk type
- Neoplasmer, kjertel og epitel
- Neoplasmer, plateepitelceller
- Neoplasmer i munnen
- Karsinom, overgangscelle
- Orofaryngeale neoplasmer
- Neoplasmer etter nettsted
- Hypofaryngeale neoplasmer
- Aminosyrer, peptider og proteiner
- Organiske kjemikalier
- Heterocykliske forbindelser, 1-ring
- Heterocykliske forbindelser
- Heterocykliske forbindelser, 2-ring
- Heterocykliske forbindelser, smeltet ringen
- Hydrokarboner
- Cycloparaffins
- Hydrokarboner, alicyklisk
- Hydrokarboner, syklisk
- Terpener
- Uorganiske kjemikalier
- Klorforbindelser
- Nitrogenforbindelser
- Guanin
- Hypoksantiner
- Purinoner
- Puriner
- Glutamater
- Aminosyrer, sure
- Aminosyrer
- Aminosyrer, dikarboksyl
- Taxoider
- Cyclodecanes
- Diterpenes
- Deoxycytidine
- Cytidin
- Pyrimidin -nukleosider
- Pyrimidiner
- Helsevesenets økonomi og organisasjoner
- Platinumforbindelser
- Økonomi
- Pemetrexed
- Gemcitabin
- Paclitaxel
- Cisplatin
- pembrolizumab
- Skatter
Andre studie-ID-numre
- Ph 1 Ph 2 INBRX-106
- KEYNOTE A99 and MK-3475-A99 (Annen identifikator: Merck Sharp & Dohme LLC)
Plan for individuelle deltakerdata (IPD)
Planlegger du å dele individuelle deltakerdata (IPD)?
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Studerer et amerikansk FDA-regulert enhetsprodukt
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .